JP2008511586A5 - - Google Patents

Download PDF

Info

Publication number
JP2008511586A5
JP2008511586A5 JP2007528875A JP2007528875A JP2008511586A5 JP 2008511586 A5 JP2008511586 A5 JP 2008511586A5 JP 2007528875 A JP2007528875 A JP 2007528875A JP 2007528875 A JP2007528875 A JP 2007528875A JP 2008511586 A5 JP2008511586 A5 JP 2008511586A5
Authority
JP
Japan
Prior art keywords
phenyl
alkyl
methoxy
substituted
morpholino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007528875A
Other languages
English (en)
Japanese (ja)
Other versions
JP5140427B2 (ja
JP2008511586A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2005/054266 external-priority patent/WO2006024640A2/en
Publication of JP2008511586A publication Critical patent/JP2008511586A/ja
Publication of JP2008511586A5 publication Critical patent/JP2008511586A5/ja
Application granted granted Critical
Publication of JP5140427B2 publication Critical patent/JP5140427B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007528875A 2004-09-02 2005-08-31 トリアゾロフタラジン Expired - Fee Related JP5140427B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04104221.9 2004-09-02
EP04104221 2004-09-02
PCT/EP2005/054266 WO2006024640A2 (en) 2004-09-02 2005-08-31 Triazolophthalazines

Publications (3)

Publication Number Publication Date
JP2008511586A JP2008511586A (ja) 2008-04-17
JP2008511586A5 true JP2008511586A5 (enExample) 2008-10-16
JP5140427B2 JP5140427B2 (ja) 2013-02-06

Family

ID=34929521

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007528875A Expired - Fee Related JP5140427B2 (ja) 2004-09-02 2005-08-31 トリアゾロフタラジン

Country Status (17)

Country Link
US (2) US7851472B2 (enExample)
EP (1) EP1791543B1 (enExample)
JP (1) JP5140427B2 (enExample)
KR (1) KR101368093B1 (enExample)
CN (1) CN101133057B (enExample)
AT (1) ATE471324T1 (enExample)
AU (1) AU2005279221C9 (enExample)
BR (1) BRPI0514586A (enExample)
CA (1) CA2578368C (enExample)
DE (1) DE602005021894D1 (enExample)
EA (1) EA014324B1 (enExample)
ES (1) ES2347337T3 (enExample)
IL (1) IL181271A (enExample)
NO (1) NO20071127L (enExample)
NZ (1) NZ553160A (enExample)
WO (1) WO2006024640A2 (enExample)
ZA (1) ZA200701137B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5240899B2 (ja) * 2005-01-05 2013-07-17 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング トリアゾロフタラジン
JP5130053B2 (ja) * 2005-01-05 2013-01-30 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング トリアゾロフタラジン
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
WO2015096651A1 (en) 2013-12-23 2015-07-02 Merck Sharp & Dohme Corp. Pyrimidone carboxamide compounds as pde2 inhibitors
US9849132B2 (en) 2014-01-08 2017-12-26 Intra-Cellular Therapies, Inc. Products and pharmaceutical compositions
RU2659070C9 (ru) 2014-04-23 2018-08-24 Дарт Нейросайенс (Кайман) Лтд. ЗАМЕЩЕННЫЕ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7-ИЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
US10239882B2 (en) 2014-11-05 2019-03-26 Dart Neuroscience (Cayman) Ltd. Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors
KR102557603B1 (ko) 2014-12-06 2023-07-19 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
CA2969597C (en) 2014-12-06 2023-10-24 Intra-Cellular Therapies, Inc. 1h-pyrazolo[4,3-c][1,5]naphthyridin-4(5h)-one compounds and their use as pde2 inhibitors
WO2016145614A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
EP3285581B1 (en) 2015-03-26 2021-08-11 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as pde2 inhibitors
WO2016179059A1 (en) 2015-05-05 2016-11-10 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as pde2 inhibitors
WO2016183741A1 (en) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Pyrimidinone amide compounds as pde2 inhibitors
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016192083A1 (en) 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
EP3313852B1 (en) 2015-06-25 2021-01-20 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
WO2017000277A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
EP3156405A1 (en) 2015-10-13 2017-04-19 Boehringer Ingelheim International GmbH Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide
PL3713572T3 (pl) 2017-11-23 2025-09-22 Oslo University Hospital Hf Leczenie tachykardii

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI81350C (fi) 1982-01-18 1990-10-10 Lepetit Spa Analogfoerfarande foer framstaellning av nya, farmakologiskt aktiva 6-substituerade s-triatsolo/3,4-a/ ftalazinderivat.
RU2128175C1 (ru) * 1994-08-09 1999-03-27 Эйсай Ко., Лтд. Конденсированный пиридазин или его фармакологически приемлемая соль, средство, проявляющее ингибирующую активность в отношении циклической гмф- фосфодиэстеразы
WO1996008496A1 (en) * 1994-09-16 1996-03-21 Takeda Chemical Industries, Ltd. Triazolopyridazines process and intermediates for their preparation and their use as medicaments
US5869486A (en) 1995-02-24 1999-02-09 Ono Pharmaceutical Co., Ltd. Fused pyrimidines and pyriazines as pharmaceutical compounds
JP4216905B2 (ja) * 1996-07-25 2009-01-28 メルク シヤープ エンド ドーム リミテツド Gaba受容体に対するリガンドとしての置換トリアゾローピリダジン誘導体
CA2288789C (en) 1997-05-08 2009-07-21 Merck Sharp & Dohme Limited Substituted 1,2,4-triazolo[3,4-a]phthalazine derivatives as gaba alpha 5 ligands
US6235741B1 (en) * 1997-05-30 2001-05-22 Merck & Co., Inc. Angiogenesis inhibitors
GB9715977D0 (en) * 1997-07-29 1997-10-01 Merck Sharp & Dohme Therapeutic agents
GB9801208D0 (en) * 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
IT1303272B1 (it) * 1998-10-29 2000-11-06 Zambon Spa Derivati triciclici inibitori della fosfodiesterasi 4
GB0028583D0 (en) 2000-11-23 2001-01-10 Merck Sharp & Dohme Therapeutic compounds
GB0108475D0 (en) * 2001-04-04 2001-05-23 Merck Sharp & Dohme New compounds
US6958334B2 (en) * 2001-04-10 2005-10-25 Merck & Co., Inc. Inhibitors of Akt activity
JP5130053B2 (ja) * 2005-01-05 2013-01-30 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング トリアゾロフタラジン
JP5240899B2 (ja) * 2005-01-05 2013-07-17 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング トリアゾロフタラジン

Similar Documents

Publication Publication Date Title
JP2008511586A5 (enExample)
JP2012507535A5 (enExample)
JP2010533722A5 (enExample)
JP2011518774A5 (enExample)
JP2010523692A5 (enExample)
HRP20160450T1 (hr) Novi inhibitori reduktaze s-nitrozoglutationa
JP2012530765A5 (enExample)
JP2015531774A5 (enExample)
JP2004508357A5 (enExample)
JP2004525951A5 (enExample)
JP2011527666A5 (enExample)
JP2009515988A5 (enExample)
JP2011513196A5 (enExample)
JP2010521514A5 (enExample)
JP2007505901A5 (enExample)
JP2010518090A5 (enExample)
JP2005539088A5 (enExample)
JP2009516727A5 (enExample)
CN101516876A (zh) 具有乙硫异烟胺活性增强作用的化合物及其用途
JP2009543795A5 (enExample)
JP2008500999A5 (enExample)
JP2010511631A5 (enExample)
JP2008516968A5 (enExample)
JP2008526692A5 (enExample)
JP2005517643A5 (enExample)